CRISPR Therapeutics AG (NASDAQ:CRSP) Given Average Rating of "Hold" by Brokerages

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) have been assigned a consensus rating of "Hold" from the twenty-one ratings firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $73.11.

A number of equities analysts recently issued reports on the company. HC Wainwright reaffirmed a "buy" rating and issued a $65.00 price target on shares of CRISPR Therapeutics in a report on Thursday, February 13th. Morgan Stanley boosted their price objective on CRISPR Therapeutics from $30.00 to $32.00 and gave the company an "underweight" rating in a research note on Friday, February 14th. Truist Financial lifted their price objective on shares of CRISPR Therapeutics from $100.00 to $120.00 and gave the company a "buy" rating in a research note on Wednesday, February 12th. Royal Bank of Canada decreased their target price on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a "sector perform" rating for the company in a research note on Wednesday, February 12th. Finally, Chardan Capital dropped their price target on CRISPR Therapeutics from $94.00 to $84.00 and set a "buy" rating on the stock in a research report on Thursday, February 13th.

CRISPR Therapeutics Price Performance

Shares of CRISPR Therapeutics stock traded up $1.25 on Thursday, reaching $42.22. 903,539 shares of the company were exchanged, compared to its average volume of 1,524,443. The stock's 50 day moving average price is $43.04 and its 200-day moving average price is $45.47. The company has a market cap of $3.62 billion, a P/E ratio of -9.61 and a beta of 1.76. CRISPR Therapeutics has a 1-year low of $36.52 and a 1-year high of $75.91.

Remove Ads

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative net margin of 981.54% and a negative return on equity of 18.46%. On average, research analysts predict that CRISPR Therapeutics will post -5.16 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Samarth Kulkarni sold 9,973 shares of CRISPR Therapeutics stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $423,054.66. Following the completion of the transaction, the chief executive officer now directly owns 180,890 shares in the company, valued at $7,673,353.80. The trade was a 5.23 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, General Counsel James R. Kasinger sold 2,850 shares of the stock in a transaction on Tuesday, March 11th. The shares were sold at an average price of $42.42, for a total value of $120,897.00. Following the sale, the general counsel now owns 77,530 shares in the company, valued at approximately $3,288,822.60. This trade represents a 3.55 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 32,381 shares of company stock worth $1,608,243. Insiders own 4.10% of the company's stock.

Hedge Funds Weigh In On CRISPR Therapeutics

Large investors have recently modified their holdings of the company. Axxcess Wealth Management LLC grew its stake in shares of CRISPR Therapeutics by 3.3% in the third quarter. Axxcess Wealth Management LLC now owns 10,271 shares of the company's stock valued at $483,000 after buying an additional 330 shares in the last quarter. State of New Jersey Common Pension Fund D grew its position in CRISPR Therapeutics by 16.8% in the third quarter. State of New Jersey Common Pension Fund D now owns 40,341 shares of the company's stock valued at $1,895,000 after acquiring an additional 5,803 shares in the last quarter. Aigen Investment Management LP purchased a new stake in CRISPR Therapeutics during the 3rd quarter worth $298,000. Oppenheimer & Co. Inc. lifted its stake in shares of CRISPR Therapeutics by 7.8% in the third quarter. Oppenheimer & Co. Inc. now owns 34,128 shares of the company's stock worth $1,603,000 after acquiring an additional 2,478 shares in the last quarter. Finally, KBC Group NV grew its holdings in CRISPR Therapeutics by 43.9% during the 3rd quarter. KBC Group NV now owns 2,818 shares of the company's stock worth $132,000 after acquiring an additional 860 shares in the last quarter. 69.20% of the stock is currently owned by hedge funds and other institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.